Viking Global Investors
Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.
Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.
View Older Stories View More Recent Stories
-
Form SC 13G/A Adaptive Biotechnologies Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Zentalis Pharmaceuticals Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A 4D Molecular Therapeutic Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Nuance Communications, Filed by: VIKING GLOBAL INVESTORS LP
-
Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First “Off-the-shelf” Genomic Medicines
-
Sema4 to Combine with SPAC, CM Life Sciences (CMLF)
-
Sema4, a Disruptive AI-driven Genomic & Clinical Data Platform Company, to Combine with CM Life Sciences to Accelerate Growth
-
Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children
-
Impossible Foods Cuts Suggested Grocery Store Prices 20%
-
Analysis: To the brink and back on GameStop - Wall Street vs Reddit
-
Viking Global Hedge Fund Down Single Digits in Market Tumult - Bloomberg
-
Impossible Foods Earns Top Score in Human Rights Campaign’s 2021 Corporate Equality Index
-
Pandemic Pushes 89 Percent of Indian IT Leaders to Protect Organizational Data from Ransomware According to New Survey
-
Top hedge funds earn $63.5 billion in 2020, highest in a decade: LCH data
-
Christiana Figueres Joins Impossible Foods’ Board of Directors
-
Druva Receives Cyber Catalyst Designation for Outstanding Product Security and Ability to Combat Ransomware
-
Form D/A Viking Global Opportunit
-
Form D/A Viking Global Opportunit
-
Affinivax Announces $226 Million Series C Financing to Advance Its Pipeline of Novel MAPS™ Vaccines Targeting Infectious Diseases
-
With Increasing Economies of Scale, Impossible Foods Delivers Double-Digit Price Reductions for the Second Time in One Year
-
Color announces $167 million in Series D financing to help build public health infrastructure across the U.S.
-
Form SC 13G/A AbCellera Biologics Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Impossible Foods Donates Its Millionth Burger and Doubles Down on Social Good For 2021
-
Form SC 13G AbCellera Biologics Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G 4D Molecular Therapeutic Filed by: VIKING GLOBAL INVESTORS LP
-
Form 4 Adaptive Biotechnologies For: Dec 14 Filed by: VIKING GLOBAL INVESTORS LP
-
IndiGo Takes to the Cloud With Druva
-
Facteus Appoints Mohammad Shaalan as Chief Data Officer
-
Conductor Raises an Additional $20 Million from Temasek, Expanding Latest Fundraising Round to $170 Million
-
Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program
-
Impossible Foods Hires Vanderbilt University Biochemistry Department Chair Dr. John D. York as Chief Science Officer
-
Boost Biomes announces extension of Series A with new investor, Universal Materials Incubator
-
RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for Cancer
-
Impossible Foods Details Extraordinary Impact of COVID-19 and Publishes All-New Sustainability Data in Annual Report
-
Druva Partners with Tech Data to Bring Cloud Data Protection to Nordics
-
Impossible Foods and Feeding America® Fight to End Hunger With “Buy Impossible Burger, Give Impossible Burger” Holiday Campaign
-
U.S. loans $1.1 billion to Ginkgo Bioworks for pandemic effort
-
Druva Supports Employees in India With Extensive Benefits as Remote Working Continues Until Spring of 2021
-
Druva Recognized for the Fifth Consecutive Year as One of the Fastest-Growing Companies in North America on Deloitte’s 2020 Technology Fast 500™
-
Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE
-
Druva Acquires sfApex to Bolster Salesforce Data Protection and Governance
-
Druva Introduces New Multi-Layered Ransomware Defense to Combat Rising Threats
-
Druva Delivers Industries Most Efficient Data Protection for Oracle Databases in Hybrid Environments
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Sep 30
-
79% of IT Leaders Look to Data Management for Competitive Advantage, According to New Survey
-
Form 4 Adaptive Biotechnologies For: Nov 11 Filed by: VIKING GLOBAL INVESTORS LP
-
Form 4 Adaptive Biotechnologies For: Nov 11 Filed by: VIKING GLOBAL PERFORMANCE LLC
-
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
-
PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
-
Ironwood Pharmaceuticals Appoints Alexander Denner, Ph.D., to Board of Directors

